Mouth Neoplasms
Conditions
Interventions
This is a two-arm, double-blind, randomized controlled clinical trial. A total of 40 people who meet the eligibility criteria will be allocated. The patients will be included according to the flow, al
GP1: patients being treated for oral and oropharyngeal cancer with grade 2 mucositis and who will use Photobiomodulation (FBM) plus placebo film) and GP2: (intervention: patients being treated for ora
Sponsors
Centro de Estudos Superiores de Maceió-CESMAC
Centro de Estudos Superiores de Maceió-CESMAC
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Participants of both sexes; aged between 18 and 64 years; under antineoplastic treatment; with oral and oropharyngeal cancer that fits into at least one of the following International Disease Classifications - ICD C01, C02, C03, C04, C05, C06, C07, C08, C09 or C10
Exclusion criteria
Exclusion criteria: Research participants with intellectual or non-collaborative difficulties that may hinder the use of the propolis-based orodispersible film and participation in complementary exams; pregnant research participants, as there is not enough evidence on the safe use of low power laser and red propolis from Alagoas for this group; research participants who present with severe immunosuppression and inability to leave the hospital environment because they are not responsive to the therapies used in the study; participants who refuse to sign the TCLE and participants who are allergic to film components (propolis and Crustaceans)]
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find an improvement in pain, within a period of 7 days, verified through the visual analogue pain scale (VAS), from the verification of a variation of at least 30% in the measurements from the beginning of the symptoms to the end of the period of treatment.;It is expected to find an improvement in healing, in a period of 7 days, verified by the healing of the lesions accompanied by clinical images photographed using a Z Flip 3 cell phone, based on the verification of a variation of at least 50% in the measurements since the onset of symptoms until the end of the treatment period. | — |
Secondary
| Measure | Time frame |
|---|---|
| secondary outcomes are not expected | — |
Countries
Brazil
Contacts
Public ContactSonia Ferreira
Centro Universitário Cesmac
Outcome results
None listed